Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
BCBioCardia, Inc. logo

BioCardia, Inc. (BCDA)

NASDAQ Capital Market · Currency in USD
$0.92 ▼ -0.01 (-0.83%)
At close: Oct 23, 4:00 PM ET. Market closed.
$0.94 ▲ +0.02 (+2.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$0.93
Open
$0.95
Day's Range
$0.91 – $0.95
52 Week Range
$0.75 – $1.80
Volume
40,281
Avg. Volume
3,146,859
Market Cap
$13.94M
Beta (5Y Monthly)
0.49
PE Ratio (TTM)
--
EPS (TTM)
-$0.61
Earnings Date
Nov 11, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: BioCardia, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
17
CEO
Peter A. Altman

BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions.

Earnings

Next report: Wed, Nov 11, 2026
EPS estimate -$0.15
DateEst.Actual
Aug 12, 2026-$0.18-$0.13Beat
May 15, 2026-$0.17-$0.21Miss
Mar 24, 2026-$0.20-$0.06Beat
Nov 12, 2025-$0.25-$0.24Beat
Aug 11, 2025-$0.25-$0.40Miss
May 14, 2025-$0.39-$0.59Miss

Analyst view

Rating: Buy
Buy 80% · Hold 20% · Sell 0%

Get free alerts on BCDA and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.